Investor Relations July 18, 2024 Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery Read More
Investor Relations July 1, 2024 Nexalin Technology Announces Closing of $5.2 Million Public Offering Read More
Investor Relations June 27, 2024 Nexalin Technology Announces Pricing of $5.2 Million Public Offering Read More
Investor Relations June 26, 2024 Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal Read More
Investor Relations June 20, 2024 Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia Read More
Investor Relations June 13, 2024 Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) Read More